Mass screening of hepatitis B and C in Burkina Faso: seroprevalence update and impact of hepatitis B vaccine

Authors

  • Armel Moumouni Sanou Laboratoire de Recherche sur les Maladies Infectieuses et Parasitaires (LR-MIP), Institut de Recherche en Sciences de la Santé (IRSS), 01 BP 545 Bobo-Dioulasso, Burkina Faso https://orcid.org/0000-0002-4969-482X
  • Delphine Napon-Zongo Institut Supérieur des Sciences de la Santé (INSSA), Université Nazi Boni, Bobo-Dioulasso, Burkina Faso https://orcid.org/0000-0002-1450-2189
  • Abou Coulibaly Laboratoire de Recherche en Santé Publique et Nutrition (LR-SPN), Institut de Recherche en Sciences de la Santé (IRSS), Burkina Faso
  • Ina Marie Angèle Traore Laboratoire de Recherche sur les Maladies Infectieuses et Parasitaires (LR-MIP), Institut de Recherche en Sciences de la Santé (IRSS), 01 BP 545 Bobo-Dioulasso, Burkina Faso
  • Ad Bafa Ibrahim Ouattara Département Clinique, Centre Assaut-Hépatites, Bobo-Dioulasso, Burkina Faso
  • Abdoul Kader Ilboudo Laboratoire de Recherche sur les Maladies Infectieuses et Parasitaires (LR-MIP), Institut de Recherche en Sciences de la Santé (IRSS), 01 BP 545 Bobo-Dioulasso, Burkina Faso https://orcid.org/0000-0001-7241-5182
  • Abdou Azaque Zoure Laboratoire de Recherche sur les Maladies Infectieuses et Parasitaires (LR-MIP), Institut de Recherche en Sciences de la Santé (IRSS), 01 BP 545 Bobo-Dioulasso, Burkina Faso https://orcid.org/0000-0002-9423-024X
  • Sylvie Zida Laboratoire de Recherche sur les Maladies Infectieuses et Parasitaires (LR-MIP), Institut de Recherche en Sciences de la Santé (IRSS), 01 BP 545 Bobo-Dioulasso, Burkina Faso
  • Mathuola Nina Geneviève Ouattara Laboratoire de Recherche sur les Maladies Infectieuses et Parasitaires (LR-MIP), Institut de Recherche en Sciences de la Santé (IRSS), 01 BP 545 Bobo-Dioulasso, Burkina Faso
  • Abdoulaye Dera Laboratoire de Recherche sur les Maladies Infectieuses et Parasitaires (LR-MIP), Institut de Recherche en Sciences de la Santé (IRSS), 01 BP 545 Bobo-Dioulasso, Burkina Faso https://orcid.org/0009-0001-3424-026X
  • Djara Konate Département des laboratoires, Centre Assaut-Hépatites, Bobo-Dioulasso, Burkina Faso
  • Eric Kyelem Laboratoire de Recherche sur les Maladies Infectieuses et Parasitaires (LR-MIP), Institut de Recherche en Sciences de la Santé (IRSS), 01 BP 545 Bobo-Dioulasso, Burkina Faso
  • Achille Sindimbasba Nikiema Laboratoire de Recherche sur les Maladies Infectieuses et Parasitaires (LR-MIP), Institut de Recherche en Sciences de la Santé (IRSS), 01 BP 545 Bobo-Dioulasso, Burkina Faso
  • David Lankoande Département Clinique, Centre Assaut-Hépatites, Bobo-Dioulasso, Burkina Faso
  • Dieudonné Ilboudo Département Clinique, Centre Assaut-Hépatites, Bobo-Dioulasso, Burkina Faso
  • Dramane Kania Centre MURAZ, Institut National de Santé Publique, Burkina Faso https://orcid.org/0000-0003-1094-5449

DOI:

https://doi.org/10.3855/jidc.19673

Keywords:

Hepatitis B, hepatitis C, seroprevalence, mass screening, epidemiology, Burkina Faso

Abstract

Introduction: Updated data on the seroprevalences of hepatitis B and C viruses (HBV, HCV) are required to enable the adaptation of control strategies. In this study, we aimed to: (i) estimate the seroprevalences of HBsAg carriers and HCV exposure in the general population, and (ii) determine the impact of vaccination on HBV circulation since its introduction in 2006 in the Expanded Program on Immunization (EPI).

Methodology: From October 2020 to October 2022, a mass screening campaign was conducted in 10 cities across Burkina Faso. Individuals of all ages and genders who consented to participate were screened for viral markers (HBsAg, anti-HCV) using rapid diagnostic tests. The proportions of HBsAg carriers and HCV exposure were calculated using Stata, and logistic regression was used to assess the impact of HBV vaccination on HBsAg carriage.

Results: A total of 15,650 participants were enrolled in the study. Of these, 51.4% were women and the age range was from 1 to 97 years. All participants were screened for HBsAg and 7,507 were also screened for anti-HCV. Overall, the seroprevalence of HBsAg was 8.8% and 2.6% for anti-HCV. The results indicated that age, gender, and place of residence were associated with HBV infection.

Conclusions: The prevalence of HBV and HCV infections remains high in Burkina Faso. Prevention strategies, including initial mass screening with rapid diagnostic tests and vaccination, need to be intensified.

Downloads

Published

2024-09-30

How to Cite

1.
Sanou AM, Napon-Zongo D, Coulibaly A, Traore IMA, Ouattara ABI, Ilboudo AK, Zoure AA, Zida S, Ouattara MNG, Dera A, Konate D, Kyelem E, Nikiema AS, Lankoande D, Ilboudo D, Kania D (2024) Mass screening of hepatitis B and C in Burkina Faso: seroprevalence update and impact of hepatitis B vaccine. J Infect Dev Ctries 18:1421–1428. doi: 10.3855/jidc.19673

Issue

Section

Original Articles